Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single-Arm, Open-Label, Dose-Escalation, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CS231295 in Patients With Advanced Solid Malignant Tumors

NCT07612488 is registered in ClinicalTrials.gov with ThalassaX Therapeutics United States Ltd as lead sponsor.

NCT NCT07612488
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07612488 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single-Arm, Open-Label, Dose-Escalation, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CS231295 in Patients With Advanced Solid Malignant Tumors
Lead sponsor
ThalassaX Therapeutics United States Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
December 31, 2028
Enrollment
42 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advance solid tumors, advanced malignant solid tumors